KR930003908A - 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 - Google Patents

염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 Download PDF

Info

Publication number
KR930003908A
KR930003908A KR1019910014711A KR910014711A KR930003908A KR 930003908 A KR930003908 A KR 930003908A KR 1019910014711 A KR1019910014711 A KR 1019910014711A KR 910014711 A KR910014711 A KR 910014711A KR 930003908 A KR930003908 A KR 930003908A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
independently
integer
defined above
Prior art date
Application number
KR1019910014711A
Other languages
English (en)
Inventor
알렌 클레멘스 제임스
앤 파네타 질
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR930003908A publication Critical patent/KR930003908A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음.

Description

염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 염증 및 관절염 치료용 약제를 제조하기 위한 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도 :
    상기식에서, R1및 R2는 서로 독립적으로 수소, C1내지 C6알킬, C1내지 C6알콕시 또는 C1내지 C4알킬(C1내지 C4알킬)이고; R3및 R4는 서로 독립적으로 수소 또는 C1내지 C4알킬이며; n은 0내지 4의 정수이고, m은 0또는 1이고, 단, m 및 n이 둘다 0일수 없으며; R5및 R는 하기 (A) 내지 (C)의 정의중 하나로 정의된다; (A)R5및 R6는 서로 독립적으로 수소, C1내지 C8알킬, C3내지 C8사이클로알킬, C2내지 C8알케닐, C2내지 C8알키닐, - (CH2)qOR7, - (CH2)qN(R7R8), - (CH2)qSR7, - (CH2)r나프틸 또는 - (CH2)r 이며, 여기서 q는 1내지 6의 정수이고, R7및 R8은 서로 독립적으로 수소 또는 C1내지 C4알킬이고, R9는 수소, 할로, C1내지 C4알킬, 트리플루오로메틸, 하이드록시, 아미노, C1내지 C4알킬아미노, 디(C1내지 C4알킬)아미노, 페닐아미노 또는 디페닐아미노이고, r은 0내지 4의 정수이거나; 또는 (B)R5및 R6중 하나는 상기(A)에 정의된 바와 같고, 다른 하나는
    (여기서, ma, na. R1a, R2a, R3a및 R4a는 각각 m, n, R1, R2, R3및 R4와 동일한 치환체이다)이거나; 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께
    또는
    를 형성하며, 여기서 R4는 상기 정의한 바와 같고, R10은 수소, C1내지 C4알킬,- (CH2)t-COOR7또는 - (CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고, s 및 t는 서로 독립적으로 0 내지 4의 정수이다)이다.
  2. 국소빈혈-유도된 세포의 손상방지용 약제를 제조하기 위한 하기 일반식(Ⅱ)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도 :
    상기식에서, R1및 R2는 서로 독립적으로 수소, C1내지 C6알킬, C1내지 C6알록시 또는 C1내지 C4알킬(C1내지 C4알킬)이고; R3및 R4는 서로 독립적으로 수소 또는 C1내지 C4알킬이며; n은 1내지 4의 정수이고; R5및 R6는 하기 (A) 내지 (C)의 정의중 하나로 정의된다; (A) R5및 R6는 서로 독립적으로 수소, C1내지 C8알킬, C3내지 C8사이클로알킬, C2내지 C8일케닐, C2내지 C8알키닐,- (CH2)q0R7,-(CH2)qN(R7R8), -(CH2)qSR7, -(CH2)r나프틸 또는 -(CH2)r -이며, 여기서 q는 1내지 6의 정수이고, R7및 R8은 서로 독립적으로 수소 또는 C1내지 C4알킬이고, R9는 수소, 할로, C1내지 C4알킬, 트리플루오로메틸, 하이드록시, 아미노, C1내지 C4알킬아미노, 디(C1내지 C4알킬)아미노, 페닐 아미노 또는 디페닐아미노이고, r은 0내지 4의 정수이거나; 또는 (B) R5및 R6중 하나는 상기(A)에 정의된 바와 같고, 다른 하나는
    (여기서, ma, na, R1a, R2a, R3a및 R4a는 각각 m, n, R1, R2, R3및 R4와 동일한 치환체이다)이거나; 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께또는를 형성
    하며, 여기서 R4는 상기 정의한 바와 같고, R10는 수소, C1내지 C4알킬,-COOR7또는 - (CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고, s 및 t는 서로 서로 독립적으로 0내지 4의 정수이다)이다.
  3. 근디스트로피 치료용 약제를 제조하기 위한 일반식(Ⅱ)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도;
    상기식에서, R1및 R2는 서로 독립적으로 수소, C1내지 C6알킬, C1내지 C6알콕시 또는 C1내지 C4알킬(C1내지 C4알킬) 이고; R3및 R4는 서로 독립적으로 수소 또는 C1내지 C4알킬이며; n은 1내지 4의 정수이고; R5및 R6는 하기(A) 내지 (C)의 정의중 하나로 정의된다; (A)R5및 R6는 서로 독립적으로 수소, C1내지 C8알킬, C3내지 C8사이클로알킬, C2내지 C8알케닐, C2내지 C8알키닐, (CH2)q0R7, - (CH2)qN(R7R8), - (CH2)qSR7, - (CH2)r 이고, 여기서, q는 1내지 6의 정수이고, R7및 R8은 서로 독립적으로 수소 또는 C1내지 C4알킬이고, R9는 수소, 할로, C1내지 C4알킬, 트리플루오로메틸, 하이드록시, 아미노, C1내지 C4알킬아미노, 디 (C1내지 C4알킬) 아미노, 페닐아미노 또는 디페닐아미노이고, r은 0 내지 4의 정수이거나; 또는 (B)R5및 R6중 하나는 상기(A)에 정의된 바와 같고, 다른 하나는
    (여기서, na, R1a, R2a, R3a및 R4a는 각각 n, R1, R2, R3및 R4와 동일한 치환체이다)이거나; 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께또는를 형성하며, 여기서 R4는 상기 정의한 바와 같고, R10은 수소, C1내지 C4알킬,또는- (CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고, s 및 t는 서로 독립적으로 0 내지 4의 정수이다)이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910014711A 1990-08-27 1991-08-24 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 KR930003908A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/572,288 US5281623A (en) 1990-08-27 1990-08-27 Method for treating inflammation
US07/572,288 1990-08-27

Publications (1)

Publication Number Publication Date
KR930003908A true KR930003908A (ko) 1993-03-22

Family

ID=24287162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910014711A KR930003908A (ko) 1990-08-27 1991-08-24 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법

Country Status (9)

Country Link
US (2) US5281623A (ko)
EP (2) EP0476846A3 (ko)
JP (1) JPH04230623A (ko)
KR (1) KR930003908A (ko)
AU (1) AU643062B2 (ko)
CA (1) CA2049902A1 (ko)
HU (1) HUT61662A (ko)
TW (1) TW199094B (ko)
ZA (1) ZA916556B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE4436127A1 (de) * 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
US5633283A (en) * 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
JPH08198756A (ja) * 1995-01-23 1996-08-06 Minsei Kagaku Kyokai 筋ジストロフィー進行抑制剤
US6028111A (en) * 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
WO2014190250A1 (en) * 2013-05-23 2014-11-27 The Johns Hopkins University Activators of soluable guanylate cyclase and their use in treatment of duchenne muscular dystrophy and related disease
JP7013375B2 (ja) * 2015-09-04 2022-01-31 シンプン・ファーマシューティカル・カンパニー・リミテッド 血小板凝集阻害効果を有する化合物及びその塩、並びにそれを含む血栓性疾患予防又は治療用組成物
US10449198B2 (en) 2016-07-01 2019-10-22 The University Of Liverpool Method for treating pain

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043774A (en) * 1955-09-23 1962-07-10 Ethyl Corp Organic compositions
NL126252C (ko) * 1961-07-28 1900-01-01 United States Rubber Co
US3305483A (en) * 1964-12-03 1967-02-21 Ethyl Corp Stabilized organic compositions
US3714365A (en) * 1970-03-12 1973-01-30 Ethyl Corp Reducing abnormally high plasma lipid levels in mammals with phenols
US3809761A (en) * 1970-03-12 1974-05-07 Ethyl Corp Method for reducing plasma lipid levels
US3792170A (en) * 1972-03-14 1974-02-12 Merck & Co Inc Novel alkylsulfinyl derivatives for pain,fever and inflammation
DE2240609A1 (de) * 1972-08-18 1974-02-28 Hoechst Ag Stoffwechselwirksame derivate der 4-hydroxy-3,5-di-alkylphenyl-propionsaeure
GB1405767A (en) * 1972-12-14 1975-09-10 Ethyl Corp Method formulation and pharmaceutical composition for reducing plasma lipid levels
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4116930A (en) * 1975-11-03 1978-09-26 Ciba-Geigy Corporation Pyromellitic dimiides of 3,5-dialkyl-4-hydroxyphenylsubstituted amines
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4128664A (en) * 1977-05-16 1978-12-05 Riker Laboratories, Inc. Substituted benzamides as anti-inflammatory agents
US4324717A (en) * 1980-06-23 1982-04-13 The B. F. Goodrich Company Norbornene polymers stabilized with hindered aromatic alcohols
US4562201A (en) * 1982-07-26 1985-12-31 American Hospital Supply Corporation Aminomethyl benzanilides
GB8301754D0 (en) * 1983-01-21 1983-02-23 Fisons Plc Formulation
IT1194325B (it) * 1983-07-19 1988-09-14 Simes Composizioni farmaceutiche comprendenti epinina o un suo sale farmaceuticamente accettabile e loro uso terapeutico
JPS6061523A (ja) * 1983-09-16 1985-04-09 Shionogi & Co Ltd 経口用ドブタミン製剤
US4532356A (en) * 1983-11-16 1985-07-30 Ethyl Corporation Chemical process
JPS61106545A (ja) * 1984-10-31 1986-05-24 Yamanouchi Pharmaceut Co Ltd ４−（ω−アミノアルキル）ピロカテコ−ル
DE3677787D1 (de) * 1985-01-15 1991-04-11 Glaxo Group Ltd Aminderivate.
GB8501646D0 (en) * 1985-01-23 1985-02-27 Nipa Lab Ltd Control of micro-organisms
GB8603765D0 (en) * 1986-02-15 1986-03-19 Beecham Wuelfung Gmbh & Co Kg Compounds
US5036157A (en) * 1986-03-11 1991-07-30 Burroughs Wellcome Co. Aryl derivatives
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
US4708966A (en) * 1986-06-27 1987-11-24 The Procter & Gamble Company Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
IT1204416B (it) * 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
US4861798A (en) * 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US5171882A (en) * 1987-01-12 1992-12-15 Eli Lilly And Company Leukotriene antagonists
JPS63185923A (ja) * 1987-01-28 1988-08-01 Otsuka Pharmaceut Factory Inc 抗炎症剤
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
PT86919B (pt) * 1987-03-10 1992-05-29 Beecham Group Plc Metodo para a utilizacao de derivados de morfolina em medicina e agricultura e respectivo processo de preparacao
ES2100148T3 (es) * 1987-09-15 1997-06-16 Rowett Research Inst Aplicaciones terapeuticas de los agonistas beta-adrenergicos.
US4948813A (en) * 1987-11-30 1990-08-14 E. I. Du Pont De Nemours And Company Benzylketone phospholipase A2 inhibitors
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
EP0385043A1 (en) * 1989-02-28 1990-09-05 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New derivatives of 4-substituted piperazines

Also Published As

Publication number Publication date
US5393786A (en) 1995-02-28
EP0476846A2 (en) 1992-03-25
ZA916556B (en) 1993-04-28
US5281623A (en) 1994-01-25
JPH04230623A (ja) 1992-08-19
TW199094B (ko) 1993-02-01
AU643062B2 (en) 1993-11-04
CA2049902A1 (en) 1992-02-28
AU8278391A (en) 1992-03-05
EP0680755A1 (en) 1995-11-08
HUT61662A (en) 1993-03-01
EP0476846A3 (en) 1992-08-05
HU912793D0 (en) 1992-01-28

Similar Documents

Publication Publication Date Title
KR920003968A (ko) 염증성 장 질환의 치료방법
KR930003908A (ko) 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법
CA2012686A1 (en) Treatment and compounds
KR870006016A (ko) N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법
ES457745A1 (es) Procedimiento para la preparacion de nuevas fluoracil-resor-cinas sustituidas.
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
KR920016089A (ko) 제i형 당뇨병의 치료방법
ES8200011A1 (es) Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa.
ES460040A1 (es) Un procedimiento para preparar derivados de 4-hidroxifeni- lalcanolaminas.
CA2002834A1 (en) Cycloalkyl xanthines
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
EP0210140A3 (en) Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases
KR910004557A (ko) 2,4,6-치환 페놀 유도체
KR830004218A (ko) 약리적 활성 펩티드
KR920014818A (ko) 항균제
MX9206930A (es) Nuevos compuestos
CA2403110A1 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
KR910005860A (ko) 항간질환성 조성물
KR900016210A (ko) 신규 화합물
KR910000645A (ko) 개선된 경련치료제
ES459755A1 (es) Procedimiento para preparar carbamatos de oximas de deriva- dos del acido isonitrosocianocetico.
IL69448A (en) Process for combating phytopathogenic fungi with azolylphenoxy-tetrahydrofuran-2-ylidene methane derivatives
IE790108L (en) Isoquinoline compounds
JPS5675428A (en) Hypoglycemic agent containing procainamide hydrochloride
GB1095220A (en) Novel benzdiaz[1,4]epine derivatives and a process for the manufacture thereof

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid